Sunday, August 2, 2015

AHA's new guidelines should leave ashes in Pharma's mouth

Cardiology news this week should leave some ashes in pharma’s mouth. The American Heart Association and the American College of Cardiology issued new guidelines for managing patients’ cholesterol.

AHA's new guidelines should leave ashes in Pharma’s mouth

0 comments

Cardiology news this week should leave some ashes in pharma’s mouth.  The American Heart Association and the American College of Cardiology issued new guidelines for managing patients’ cholesterol.

For several decades patients were prescribed medications, mainly statins, to alter their cholesterol levels based almost entirely upon readings for total cholesterol and the LDL and HDL “fractions.”  Under the financial lure of research grants from pharma companies, these professional societies and their esteemed Key Opinion Leaders kept making the target cholesterol levels more difficult to achieve.  This had the effect of pushing physicians to prescribe ever stronger statins to a larger number of people.  In the process pharma companies earned billions in sales for their branded statins — Lipitor, Zocor, Crestor and others.

Under the new guidelines, the same target cholesterol levels don't apply to everyone and pharma's longstanding admonition to physicians, the-lower-the-better, is revealed as the promotional dodge it's always been.  While a set of cholesterol numbers in one person may warrant statin therapy depending upon that person's history, the same numbers in someone with a different history may indicate that no drug therapy is needed.

Ironically, some researchers anticipate that more people will become eligible for statin therapy under the new guidelines, although the fact that the top-selling statins, except for AstraZeneca's Crestor, are now off-patent won't benefit the branded pharma companies.

This situation is not one where pharma companies promoted their statins for twenty-plus years under the best guidelines that were in force at the time but now are obsolete.  Most office-based cardiologists always knew that cholesterol levels represented just one of several factors to be taken into account when determining the course of treatment.  It's just that the increasingly demanding target levels mandated by the professional societies, under pharma's financial lures, kept raising the legal liability concerns among garden variety cardiologists and encouraged them to spread more statins around.


Read more from the Check Up blog »

President, Pharmaceutical Business Research Associates
0 comments
We encourage respectful comments but reserve the right to delete anything that doesn't contribute to an engaging dialogue.
Help us moderate this thread by flagging comments that violate our guidelines.

Comment policy:

Philly.com comments are intended to be civil, friendly conversations. Please treat other participants with respect and in a way that you would want to be treated. You are responsible for what you say. And please, stay on topic. If you see an objectionable post, please report it to us using the "Report Abuse" option.

Please note that comments are monitored by Philly.com staff. We reserve the right at all times to remove any information or materials that are unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane, indecent or otherwise objectionable. Personal attacks, especially on other participants, are not permitted. We reserve the right to permanently block any user who violates these terms and conditions.

Additionally comments that are long, have multiple paragraph breaks, include code, or include hyperlinks may not be posted.

Read 0 comments
 
comments powered by Disqus
About this blog

Check Up covers regional health news and a wide array of healthcare topics from pharmaceutical happenings to patient safety. Read about some of our bloggers here.

Portions of this blog may also be found in the Inquirer's Sunday Health Section.

Michael R. Cohen, R.Ph. President, Institute for Safe Medication Practices
Daniel R. Hoffman, Ph.D. President, Pharmaceutical Business Research Associates
Hooman Noorchashm, M.D., Ph.D. Cardiothoracic surgeon in the Philadelphia area
Amy J. Reed, M.D., Ph.D. Anesthesiologist and Surgical Intensivist in the Philadelphia Area
Latest Health Videos
Also on Philly.com:
letter icon Newsletter